Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.

Wei M, Gao CJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):1064-70. Review.

PMID:
21867645
2.

Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.

Bisen A, Claxton DF.

Adv Exp Med Biol. 2013;779:179-96. doi: 10.1007/978-1-4614-6176-0_8. Review.

PMID:
23288640
3.

Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.

Tefferi A, Levine RL, Kantarjian H.

Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):114-9. doi: 10.1016/j.bbmt.2008.10.010. Review.

4.

Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

Hochhaus A, Reiter A, Ernst T, La Rosée P.

Onkologie. 2012;35 Suppl 1:34-41. doi: 10.1159/000334824. Epub 2012 Jan 20.

PMID:
22286586
6.
7.

Deactylase inhibition in myeloproliferative neoplasms.

Mithraprabhu S, Grigoriadis G, Khong T, Spencer A.

Invest New Drugs. 2010 Dec;28 Suppl 1:S50-7. doi: 10.1007/s10637-010-9590-4. Epub 2010 Dec 3. Review.

8.

[Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].

Schmitt-Graeff AH.

Pathologe. 2010 Feb;31(1):29-41. doi: 10.1007/s00292-009-1261-x. Review. German.

PMID:
20076959
9.

Chronic myeloproliferative disorders: a tyrosine kinase tale.

De Keersmaecker K, Cools J.

Leukemia. 2006 Feb;20(2):200-5. Review.

PMID:
16341034
10.

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Wadleigh M, Tefferi A.

Int J Hematol. 2010 Mar;91(2):174-9. doi: 10.1007/s12185-010-0529-5. Epub 2010 Feb 27. Review.

PMID:
20191332
11.

The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.

Tefferi A, Thiele J, Vardiman JW.

Cancer. 2009 Sep 1;115(17):3842-7. doi: 10.1002/cncr.24440.

12.

Off-Target Effects of BCR-ABL and JAK2 Inhibitors.

Green MR, Newton MD, Fancher KM.

Am J Clin Oncol. 2016 Feb;39(1):76-84. doi: 10.1097/COC.0000000000000023. Review.

PMID:
24351780
13.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

Treliński J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159
14.

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Pardanani A, Tefferi A.

Blood. 2004 Oct 1;104(7):1931-9. Epub 2004 May 27. Review.

15.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
16.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
17.

The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.

Berzoti-Coelho MG, Ferreira AF, de Souza Nunes N, Pinto MT, Júnior MC, Simões BP, Martínez-A C, Souto EX, Panepucci RA, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2016 Jul;59:25-30. doi: 10.1016/j.bcmd.2016.03.008. Epub 2016 Apr 8.

PMID:
27282563
18.

Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update.

Anastasiadou E, Schwaller J.

Curr Opin Hematol. 2003 Jan;10(1):40-8. Review.

PMID:
12483110
19.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
20.

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Kumar C, Purandare AV, Lee FY, Lorenzi MV.

Oncogene. 2009 Jun 18;28(24):2305-13. doi: 10.1038/onc.2009.107. Epub 2009 May 4. Review.

PMID:
19421140

Supplemental Content

Support Center